CA2835916A1 - 3-spirocyclic piperidine derivatives as ghrelin receptor agonists - Google Patents

3-spirocyclic piperidine derivatives as ghrelin receptor agonists Download PDF

Info

Publication number
CA2835916A1
CA2835916A1 CA2835916A CA2835916A CA2835916A1 CA 2835916 A1 CA2835916 A1 CA 2835916A1 CA 2835916 A CA2835916 A CA 2835916A CA 2835916 A CA2835916 A CA 2835916A CA 2835916 A1 CA2835916 A1 CA 2835916A1
Authority
CA
Canada
Prior art keywords
oxo
methyl
amino
decan
diazaspiro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2835916A
Other languages
English (en)
French (fr)
Inventor
Ameet Vijay AMBARKHANE
Gurdip Bhalay
Martin BECKETT
James Dale
Ahmed HAMADI
Alessandro Mazzacani
Jeffrey Mckenna
Christopher Thomson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46317469&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2835916(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of CA2835916A1 publication Critical patent/CA2835916A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
CA2835916A 2011-05-27 2012-05-25 3-spirocyclic piperidine derivatives as ghrelin receptor agonists Abandoned CA2835916A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161490848P 2011-05-27 2011-05-27
US61/490,848 2011-05-27
US201161560960P 2011-11-17 2011-11-17
US61/560,960 2011-11-17
US201261642116P 2012-05-03 2012-05-03
US61/642,116 2012-05-03
PCT/IB2012/052649 WO2012164473A1 (en) 2011-05-27 2012-05-25 3-spirocyclic piperidine derivatives as ghrelin receptor agonists

Publications (1)

Publication Number Publication Date
CA2835916A1 true CA2835916A1 (en) 2012-12-06

Family

ID=46317469

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2835916A Abandoned CA2835916A1 (en) 2011-05-27 2012-05-25 3-spirocyclic piperidine derivatives as ghrelin receptor agonists

Country Status (21)

Country Link
US (2) US8546416B2 (es)
EP (1) EP2714690A1 (es)
JP (1) JP2014515369A (es)
KR (1) KR20140023399A (es)
CN (1) CN103562206A (es)
AP (1) AP2013007234A0 (es)
AR (1) AR086554A1 (es)
AU (1) AU2012264305A1 (es)
BR (1) BR112013030391A2 (es)
CA (1) CA2835916A1 (es)
CL (1) CL2013003211A1 (es)
CO (1) CO6811856A2 (es)
CR (1) CR20130625A (es)
EA (1) EA201391797A1 (es)
IL (1) IL229320A0 (es)
MX (1) MX355072B (es)
PE (1) PE20140610A1 (es)
SG (1) SG194616A1 (es)
TW (1) TW201302749A (es)
UY (1) UY34094A (es)
WO (1) WO2012164473A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013255458A1 (en) * 2012-05-03 2014-10-09 Novartis Ag L-malate salt of 2, 7 - diaza - spiro [4.5 ] dec- 7 - yle derivatives and crystalline forms thereof as ghrelin receptor agonists
WO2014026013A2 (en) 2012-08-09 2014-02-13 Dynamis Therapeutics, Inc. Methods for maintaining or improving health, well-being and/or a physiological function in a subject
MD20160116A2 (ro) 2014-04-04 2017-04-30 X-Rx Discovery, Inc Inhibitori spirociclici substituiţi ai autotaxinei
JP2017532350A (ja) * 2014-10-31 2017-11-02 ラクオリア創薬株式会社 グレリン受容体アゴニストとしてのテトラヒドロピラゾロピリジン誘導体
JP2020519639A (ja) * 2017-05-12 2020-07-02 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． トリアザスピロ［４．５］デカノンによる胃不全麻痺の処置
CN111175387B (zh) * 2018-11-13 2022-06-07 成都康弘药业集团股份有限公司 一种米那普仑异构体的检测方法
CN113125583B (zh) * 2019-12-30 2022-06-21 成都百裕制药股份有限公司 一种注射用泮托拉唑钠中基因毒性杂质含量的检测方法
US20230174531A1 (en) * 2021-12-08 2023-06-08 Enanta Pharmaceuticals, Inc. Saturated spirocyclics as antiviral agents

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5578593A (en) 1992-12-11 1996-11-26 Merck & Co., Inc. Spiro piperidines and homologs promote release of growth hormone
SK282166B6 (sk) * 1992-12-11 2001-11-06 Merck & Co., Inc. Spiropiperidínové deriváty, spôsob ich výroby a farmaceutický prostriedok s ich obsahom
EP0828754B1 (en) 1995-05-29 2005-02-02 Pfizer Inc. Dipeptides which promote release of growth hormone
US6403599B1 (en) 1995-11-08 2002-06-11 Pfizer Inc Corticotropin releasing factor antagonists
WO1997011697A1 (en) * 1995-09-26 1997-04-03 Merck & Co., Inc. 3-spirolactam, 3-spiroamino, 3-spirolactone and 3-spirobenzopyran piperidines and pyrrolidines promote release of growth hormone
WO1997044042A1 (en) 1996-05-22 1997-11-27 Arch Development Corporation Sleep quality improvement using a growth hormone secretagogue
UA64751C2 (uk) 1997-06-25 2004-03-15 Пфайзер Продактс Інк. Спосіб лікування інсулінової толерантності речовинами, які посилюють секрецію гормону росту (варіанти) та фармацевтична композиція (варіанти)
AU7445498A (en) * 1997-06-25 1999-01-04 Pfizer Inc. Dipeptide derivatives as growth hormone secretagogues
TW544448B (en) 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
US6329342B1 (en) 1997-08-19 2001-12-11 Eli Lilly And Company Treatment of congestive heart failure with growth hormone secretagogues
ZA987385B (en) 1997-08-19 2000-04-18 Lilly Co Eli Growth hormone secretagogues.
GB9802251D0 (en) 1998-02-03 1998-04-01 Ciba Geigy Ag Organic compounds
ID29095A (id) 1998-10-02 2001-07-26 Novartis Ag Cs Antagonis mglur5 untuk pengobatan rasa sakit dan kegelisahan
US6194578B1 (en) 1998-11-20 2001-02-27 Pfizer Inc. Dipeptide derivatives
SI1004583T1 (en) 1998-11-23 2004-12-31 Pfizer Products Inc. Process and hydantoin intermediates for the synthesis of growth hormone secretagogues
GB9913079D0 (en) 1999-06-04 1999-08-04 Novartis Ag Organic compounds
DOP2001000154A (es) 2000-05-25 2002-05-15 Pfizer Prod Inc Combinación de secretagogos de hormona del crecimiento y antidepresivos
ATE446758T1 (de) 2000-05-31 2009-11-15 Pfizer Prod Inc Verwendung von wachstumshormonsekretagoga zur förderung der beweglichkeit des verdauungstrakts
IL143690A0 (en) 2000-06-19 2002-04-21 Pfizer Prod Inc The use of growth hormone secretagogues to treat systemic lupus erythematosus and inflammatory bowel disease
GB0028702D0 (en) 2000-11-24 2001-01-10 Novartis Ag Organic compounds
KR20030083755A (ko) 2001-03-26 2003-10-30 노파르티스 아게 동통 치료를 위한 바닐로이드 수용체 길항제로서의 용도를위한 융합 피리딘 유도체
DE60235536D1 (de) 2001-05-14 2010-04-15 Novartis Ag Sulfonamidderivate
JP3894035B2 (ja) 2001-07-04 2007-03-14 東レ株式会社 炭素繊維強化基材、それからなるプリフォームおよび複合材料
TW200306839A (en) 2002-02-06 2003-12-01 Novartis Ag Quinazolinone derivatives and their use as CB agonists
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
WO2003087036A1 (en) 2002-04-10 2003-10-23 Eli Lilly And Company Stereoselective process for the synthesis of (d)-2-amino-5-phenylpentanoic or alkyl ester thereof
US6696468B2 (en) 2002-05-16 2004-02-24 Dainippon Pharmaceutical Co., Ltd. (s)-4-amino-5-chloro-2-methoxy-n-[1-[1-(2-tetrahydrofuryl-carbonyl)-4-piperidinylmethyl]-4-piperidinyl]benzamide, process for the preparation thereof, pharmaceutical composition containing the same, and intermediate therefor
SE0201940D0 (sv) 2002-06-20 2002-06-20 Astrazeneca Ab New combination II
DOP2003000703A (es) 2002-09-20 2004-03-31 Pfizer Compuestos de imidazopiradina como agonistas del receptor 5-ht4
GB0223730D0 (en) 2002-10-11 2002-11-20 Novartis Ag Organic compounds
PE20040844A1 (es) 2002-11-26 2004-12-30 Novartis Ag Acidos fenilaceticos y derivados como inhibidores de la cox-2
GB0302876D0 (en) 2003-02-07 2003-03-12 Novartis Ag Organic compounds
JP2004277319A (ja) 2003-03-14 2004-10-07 Dainippon Pharmaceut Co Ltd １−（４−ピペリジニルメチル）ピペリジニルアミド誘導体およびそれを含有する医薬組成物
JP2004277318A (ja) 2003-03-14 2004-10-07 Dainippon Pharmaceut Co Ltd １−（１−置換カルボニル−４−ピペリジニルメチル）ピペリジン誘導体およびそれを含有する医薬組成物
CA2525502C (en) 2003-05-21 2012-12-18 Prosidion Limited Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase
EP1505064A1 (en) 2003-08-05 2005-02-09 Bayer HealthCare AG 2-Aminopyrimidine derivatives
CN100398524C (zh) 2003-08-12 2008-07-02 弗·哈夫曼-拉罗切有限公司 作为crf拮抗剂的四氢喹唑啉衍生物
JP2007501822A (ja) 2003-08-12 2007-02-01 エフ．ホフマン−ラ　ロシュ　アーゲー コルチコトロピン放出性因子（ｃｒｆ）アンタゴニストとしてのスピロ置換テトラヒドロキナゾリン
EP1664010A1 (en) 2003-08-29 2006-06-07 Vernalis (R&D) Limited Sulfonamides antagonising n-type calcium channels
WO2005028480A2 (en) 2003-09-03 2005-03-31 Neurogen Corporation 5-aryl-pyrazolo[4,3-d]pyrimidines, pyridines, and pyrazines and related compounds
GEP20084527B (en) 2003-09-03 2008-11-10 Pfizer Benzimidazolone compounds having 5-ht4 receptor agonistic activity
JP2005082508A (ja) 2003-09-05 2005-03-31 Dainippon Pharmaceut Co Ltd ２−アルコキシ−６−アミノ−５−ハロゲノ−ｎ−（１−置換−４−ピペリジニル）ピリジン−３−カルボキサミド誘導体およびそれを含有する医薬組成物
CN1878773A (zh) 2003-09-05 2006-12-13 神经能质公司 作为crf1受体配位体的杂芳基稠合的吡啶,吡嗪及嘧啶
US20070027156A1 (en) 2003-09-09 2007-02-01 Hisao Nakai Crf antagonists and heterobicyclic compounds
GB0322612D0 (en) 2003-09-26 2003-10-29 Novartis Ag Organic compounds
EP1673348B1 (en) 2003-09-30 2009-04-01 Janssen Pharmaceutica N.V. Benzoimidazole compounds
JP2005104896A (ja) 2003-09-30 2005-04-21 Dainippon Pharmaceut Co Ltd ２−アルコキシ−６−アミノ−５−ハロゲノピリジン−３−カルボキサミド誘導体およびそれを含有する医薬組成物
JP2007507514A (ja) 2003-09-30 2007-03-29 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ キノキサリン化合物
US7714009B2 (en) 2003-10-31 2010-05-11 Takeda Pharmaceutical Company Limited Nitrogen-containing fused heterocyclic compounds
US20090074890A1 (en) 2003-11-10 2009-03-19 Park Min K Substituted Triazoles as Sodium Channel Blockers
US7208596B2 (en) 2003-11-25 2007-04-24 Bristol-Myers Squibb Pharma Company Processes for the preparation of pyrazolo[1,5-a]-1,3,5-triazines and intermediates thereof
WO2005054239A1 (en) 2003-12-05 2005-06-16 Bayer Healthcare Ag 2-aminopyrimidine derivatives
US7211568B2 (en) 2003-12-18 2007-05-01 Kosan Biosciences Incorporated 9-Desoxoerythromycin compounds as prokinetic agents
JP2005206590A (ja) 2003-12-25 2005-08-04 Mitsubishi Pharma Corp ナトリウムチャネルサイト２選択的阻害剤
MXPA06007853A (es) 2004-01-07 2007-01-26 Aryx Therapeutics Compuestos estereoisomericos y metodos para el tratamiento de desordenes gastrointestinales y del sistema nervioso central.
ATE388146T1 (de) 2004-01-29 2008-03-15 Pfizer 1-isopropyl-2-oxo-1,2-dihydropyridin-3- carbonsäureamidderivate mit agonistischer wirkung am 5-ht4-rezeptor
TW200533348A (en) 2004-02-18 2005-10-16 Theravance Inc Indazole-carboxamide compounds as 5-ht4 receptor agonists
WO2005092882A1 (en) 2004-03-01 2005-10-06 Pfizer Japan, Inc. 4-amino-5-halogeno-benzamide derivatives as 5-ht4 receptor agonists for the treatment of gastrointestinal, cns, neurological and cardiovascular disorders
EP1574478A1 (de) 2004-03-08 2005-09-14 Solvay Fluor GmbH Herstellung von Carbonylfluorid
CN101022728B (zh) 2004-03-25 2012-08-08 詹森药业有限公司 咪唑化合物
US20080280873A1 (en) 2004-03-29 2008-11-13 Jun Liang Biaryl Substituted Pyrazinones as Sodium Channel Blockers
TWI351282B (en) 2004-04-07 2011-11-01 Theravance Inc Quinolinone-carboxamide compounds as 5-ht4 recepto
US20080015196A1 (en) 2004-04-16 2008-01-17 Neurogen Corporation Imidazopyrazines, Imidazopyridines, and Imidazopyrimidines as Crf1 Receptor Ligands
GB0412768D0 (en) 2004-06-08 2004-07-07 Novartis Ag Organic compounds
GB0412769D0 (en) 2004-06-08 2004-07-07 Novartis Ag Organic compounds
MXPA06014486A (es) 2004-06-15 2007-03-01 Pfizer Derivados de acido carboxilico de bencimidazolona.
SE0401653D0 (sv) 2004-06-24 2004-06-24 Astrazeneca Ab New compounds
WO2006023757A2 (en) 2004-08-19 2006-03-02 University Of Virginia Patent Foundation Novel tricyclic, bicyclic, monocyclic, and acyclic amines as potent sodium channel blocking agents
GB0420424D0 (en) 2004-09-14 2004-10-20 Ionix Pharmaceuticals Ltd Therapeutic compounds
WO2006038594A1 (ja) 2004-10-04 2006-04-13 Ono Pharmaceutical Co., Ltd. Ｎ型カルシウムチャネル阻害薬
GB0519957D0 (en) 2005-09-30 2005-11-09 Sb Pharmco Inc Chemical compound
US7396933B2 (en) 2004-11-05 2008-07-08 Theravance, Inc. Quinolinone-carboxamide compounds
EP1807422B1 (en) 2004-11-05 2009-09-02 Theravance, Inc. 5-ht4 receptor agonist compounds
US20080269239A1 (en) 2004-11-11 2008-10-30 Argenta Discovery Ltd. Pyrimidine Compounds as Histamine Modulators
US20060111416A1 (en) 2004-11-24 2006-05-25 Lane Charlotte A L Octahydropyrrolo[3,4-C]pyrrole derivatives
ATE469897T1 (de) 2004-12-22 2010-06-15 Theravance Inc Indazolcarbonsäureamidverbindungen
EP1818061A1 (en) 2005-12-02 2007-08-15 Charite-Universitätsmedizin Berlin Use of ghrelin for stimulating hair growth
US7601844B2 (en) 2006-01-27 2009-10-13 Bristol-Myers Squibb Company Piperidinyl derivatives as modulators of chemokine receptor activity
JP2010518090A (ja) 2007-02-09 2010-05-27 トランザイム・ファーマ，インコーポレイテッド 大環状グレリン受容体修飾因子およびその使用方法
US7994203B2 (en) 2008-08-06 2011-08-09 Novartis Ag Organic compounds
US8273900B2 (en) 2008-08-07 2012-09-25 Novartis Ag Organic compounds
BR112012007183A2 (pt) 2009-09-30 2017-06-20 Tranzyme Pharma Inc solvato de um sal de um composto macrocíclico, forma polimórfica, processos para preparar a forma polimórfica e uma composição farmacêutica, composição farmacêutica, sal de um composto macrocíclico, e, métodos para estimular motilidade gastrintestinal, para tratar um distúrbio gastrintestinal e para tratar um indivíduo, e, kit

Also Published As

Publication number Publication date
AU2012264305A1 (en) 2013-11-21
MX355072B (es) 2018-04-04
TW201302749A (zh) 2013-01-16
PE20140610A1 (es) 2014-05-31
AR086554A1 (es) 2014-01-08
IL229320A0 (en) 2014-01-30
US20120302540A1 (en) 2012-11-29
CN103562206A (zh) 2014-02-05
AP2013007234A0 (en) 2013-11-30
CL2013003211A1 (es) 2014-07-04
KR20140023399A (ko) 2014-02-26
SG194616A1 (en) 2013-12-30
JP2014515369A (ja) 2014-06-30
US8546416B2 (en) 2013-10-01
CO6811856A2 (es) 2013-12-16
CR20130625A (es) 2014-02-04
WO2012164473A1 (en) 2012-12-06
EA201391797A1 (ru) 2014-04-30
UY34094A (es) 2013-01-03
BR112013030391A2 (pt) 2016-12-13
MX2013013950A (es) 2014-01-23
EP2714690A1 (en) 2014-04-09
US20130331369A1 (en) 2013-12-12

Similar Documents

Publication Publication Date Title
US8546416B2 (en) 3-spirocyclic piperidine derivatives as ghrelin receptor agonists
US11639353B2 (en) Cyclobutanes- and azetidine-containing mono and spirocyclic compounds as αV integrin inhibitors
US20200155690A1 (en) Cereblon ligands and bifunctional compounds comprising the same
TWI630206B (zh) 經胺基－取代之咪唑并［１，２－ａ］吡啶羧醯胺類及其用途
TWI740843B (zh) 用於抑制ｊａｋ之化合物和方法
EA031967B1 (ru) ДИГИДРОПИРРОЛОПИРИДИНОВЫЕ ИНГИБИТОРЫ ROR-γ
NZ528270A (en) Drugs containing triazaspiro[5.5]undecane derivatives as the active ingredient
TWI596095B (zh) Dihydropyridazine-3,5-dione derivatives
JP2022078137A (ja) アミノピリジン誘導体およびそれらの選択的ａｌｋ－２阻害剤としての使用
EP2875016A1 (en) Carbamate/urea derivatives
CA2867043A1 (en) L-malate salt of 2,7-diaza-spiro[4.5]dec-7-yle derivatives and crystalline forms thereof as ghrelin receptor agonists
JP2017529330A (ja) 置換キノリン−４−カルボキサミドおよびその使用
KR20190040340A (ko) 장애의 치료를 위한 하이드록시노르케타민 유도체

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140212

FZDE Discontinued

Effective date: 20160525